Lung Cancer Diagnostic and Screening Market, By Test Type (Biomarkers Test (EGFR Mutation Test, KRAS Mutation Test, ALK Test, HER2 Test, Others) Imaging Test (Computed Tomography (CT) scan, Positron Emission Tomography (PET) scan, Chest X-Ray, Others), Biopsy), By Cancer Type (Non-small cell lung cancer, Small Cell Lung CancerNeurosurgery), By End User (Hospital Associated Labs, Independent Diagnostic Laboratories, Cancer Research Institutes, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Oct 2023

Code : CMI4434

Pages :180

Formats :

Excel and PDF

Industry : Clinical Diagnostic

Lung Cancer Diagnostic And Screening MarketSize and Trends

The global lung cancer diagnostic and screening market is estimated to be valued at US$ 2,458.7 million in 2023 and is expected to exhibit a CAGR of 10.1% during the forecast period (2023-2030).

Figure 1. Global Lung Cancer Diagnostic and Screening Market Share (%), By Test Type, 2023

Global Lung Cancer Diagnostic and Screening Market– Drivers

Increasing Research & Development activities for early detection of cancer: Increasing Research & Development activities for early detection of cancer are expected to propel the growth of the global lung cancer diagnostic and screening market over the forecast period. For instance, in April 2020, researchers at the Massachusetts Institute of Technology (MIT) developed a nanoparticle-based approach that allows the early diagnosis of lung cancer through a simple urine test. The strategy detects biomarkers resulting from the interaction of peptide-coated nanoparticles with disease-associated proteases in the tumor microenvironment. Experiments in two different mouse models of lung cancer showed that the urine test could detect tumors as small as 2.8 mm. The researchers hope that this type of noninvasive diagnosis could reduce the number of false positives associated with an existing test method and help to detect more tumors in the early stages of the disease.
Increasing prevalence of lung cancer due to changes in lifestyle and increasing consumption and production of tobacco: The increasing prevalence of lung cancer due to changes in lifestyle and increasing consumption and production of tobacco is expected to increase the demand for surgical equipment, thereby driving the global lung cancer diagnostic and screening market growth. When discussing and analysing long-term personal development, it is important to constantly take into account the lifestyle that people are raised in or choose when autonomously shaping their lives. Smoking constituted an important symbolic gadget, suggesting the user’s free and modern lifestyle. As was proven, smoking comes with a high price for health. Lifestyle habits are, however, multicomponent behaviors, including, diet, exercise, sleep, and alcohol and/or other substance use. On the other hand, smoking as a lifestyle has been in vogue, which makes it a global public health problem and a major cause of lung cancer. Thus, the increasing rate of smoking and tobacco consumption around the world due to change in lifestyle is expected to fuel market growth over the forecast period. In May 2022, according to a report published by the World Health Organization (WHO), tobacco kills more than 8 million people worldwide each year. Whereas more than 7 million of those deaths are the result of direct tobacco use, approximately 1.2 million are the result of non-smokers being exposed to second-hand smoke.

Global Lung Cancer Diagnostic and Screening Market- Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global lung cancer diagnostic and screening market over the forecast period. North America is estimated to hold 33.5% of the market share in 2023. The global lung cancer diagnostic and screening market is expected to witness significant growth in the coming years, driven by the high prevalence of lung cancer. The increasing prevalence of neurological disorders is contributing to the growth of the lung cancer diagnostic and screening market in the North America region. For instance, according to data published by the American Society of Clinical Oncology (ASCO) on March 3, 2023, worldwide, lung cancer is the second most commonly diagnosed cancer, while NSCLC (non-small cell lung cancer) is the most common type of lung cancer in the U.S., accounting for 81% of all lung cancer diagnoses.